Explore

Trendline Trendline
Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action

Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action

Rosen Law Firm Urges GRAIL, Inc. Investors to Act Before August 4 Deadline in Securities Class Action
Trendline Trendline
Rosen Law Firm Urges GRAIL Investors to Act Before Class Action Deadline

Rosen Law Firm Urges GRAIL Investors to Act Before Class Action Deadline

Rosen Law Firm Urges GRAIL Investors to Act Before Class Action Deadline
Trendline Trendline
Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Financial Challenges

Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Financial Challenges

Novartis Reports Q2 Sales Growth and Pipeline Advancements Amidst Financial Challenges
Trendline Trendline
Summit Therapeutics Reports Financial and Clinical Progress for Q2 2026

Summit Therapeutics Reports Financial and Clinical Progress for Q2 2026

Summit Therapeutics Reports Financial and Clinical Progress for Q2 2026
Trendline Trendline
Summit Therapeutics Reports Financial Results and Progress in Ivonescimab Trials

Summit Therapeutics Reports Financial Results and Progress in Ivonescimab Trials

Summit Therapeutics Reports Financial Results and Progress in Ivonescimab Trials
Trendline Trendline
Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors

Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors

Bio-Thera Solutions Initiates Phase 1 Study for BAT8013 Targeting CD25 in Advanced Solid Tumors
Trendline Trendline
AtriCure Announces Strong Second Quarter 2026 Financial Results with Increased Revenue and Profitability

AtriCure Announces Strong Second Quarter 2026 Financial Results with Increased Revenue and Profitability

AtriCure Announces Strong Second Quarter 2026 Financial Results with Increased Revenue and Profitability
Trendline Trendline
CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs

CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs

CytoDyn Expands Access to Cancer Patients with Innovative Clinical Programs
Trendline Trendline
Booz Allen Hamilton Reports Q2 CY2026 Revenue Below Analyst Expectations

Booz Allen Hamilton Reports Q2 CY2026 Revenue Below Analyst Expectations

Booz Allen Hamilton Reports Q2 CY2026 Revenue Below Analyst Expectations
Trendline Trendline
MaxLinear Reports Strong Q2 Earnings with Significant Revenue Growth

MaxLinear Reports Strong Q2 Earnings with Significant Revenue Growth

MaxLinear Reports Strong Q2 Earnings with Significant Revenue Growth
Trendline Trendline
Signify Faces Challenges Amid Tariff Uncertainty and Declining Profits

Signify Faces Challenges Amid Tariff Uncertainty and Declining Profits

Signify Faces Challenges Amid Tariff Uncertainty and Declining Profits
Trendline Trendline
Intel's Q2 Performance Boosts Stock, Increases AI Investment Outlook

Intel's Q2 Performance Boosts Stock, Increases AI Investment Outlook

Intel's Q2 Performance Boosts Stock, Increases AI Investment Outlook